面向国际患者的CAR-T、干细胞、医疗旅游和医疗政策最新动态。AI精选并标注来源。
There is a new option for cancer treatment: more and more international patients are choosing to receive CAR-T cell therapy in China, where the cost is only about one-fifth of comparable treatment in the US, while clinical efficacy is equally recognized internationally. This combination of price and
Read articleCAR-T cell therapy is accelerating in Shanghai, providing international patients with a new treatment option. As one of China's most active cities for medical technology innovation, Shanghai has multiple medical institutions carrying out CAR-T treatment, with cost advantages compared with Europe and
Read articleMore and more international patients are choosing to seek treatment in China, behind which are real and heartwarming stories. From overcoming difficult tumors, to successfully receiving assisted reproduction, to cost-effective health checkups, Chinese healthcare is winning the trust of global patien
Read articleAllogeneic CAR-T cell therapy has entered the clinical stage. This off-the-shelf therapy is expected to significantly reduce treatment costs and shorten waiting times. Unlike autologous CAR-T which requires collecting the patient's own cells, allogeneic products come from healthy donors, can be prod
Read articleGood news has arrived in the field of multiple myeloma treatment: dual-target CAR-T therapy has achieved deep remission. The dual-target design significantly reduces the risk of drug resistance caused by loss of a single antigen, improves treatment durability, and brings new hope to patients who hav
Read articleA study pooling data from multiple medical centers in China shows that the cost-effectiveness of CAR-T cell therapy for relapsed or refractory lymphoma has gained international recognition. Using data with a median follow-up of 18 months, the study demonstrates the outstanding performance of CAR-T i
Read articleCAR-T cell therapy is reshaping the treatment landscape for lymphoma patients in China. Data released by multiple medical institutions show that more than 60% of patients with large B-cell lymphoma who received CAR-T therapy have achieved five-year survival, and some patients with relapsed or refrac
Read articleChina's NMPA has approved the world's first CAR-T cell therapy drug for solid tumors (gastrointestinal), marking China's renewed global leadership in cell therapy.
Read articleGet the latest medical insights and healthcare news delivered to your inbox.